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placebo treated control) in intima/media ratio paralleled by accelerated endothelial cover- 
age and reduced intimal call number. 
Conclusions: The combination treatment with VEGF-C adenovirus and STI571 led to a 
long-lasting inhibition of intimal thickening. Our study is one of the first successful exam- 
plas of gene therapy combined with pharmacological treatment and provides a novel 
principle to prevent intimal hyperplasia fter vascular intervention. 
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Novel Tissue Factor Targeted Therapy Inhibits Vascular 










Graaorv M, Lanza. Dana R. Ahendschein, Michael J. Scott, Ralph W. Fuhrhop, David E. 
Schsrrar, Kerry Karukstis, Samuel A, Wicklins, Washington Universi~, St. Louis, 
Missouri, Harvey Mudd College, Claremont, California. 
Stect-based antiproliferative delivery systems create high lumen drug concentrations in 
order to achieve therapeutic dosage levels within the tunics media..High intima drug lev- 
els of antiproliferative agents induce inflammation, impede endothelial regrowth, and 
delay artedal wall healing. We have developed a tissue factor (TF)-targeted peramag- 
netic nanoparticle that specifically binds to vascular smooth muscle cells (VSMC) and 
provides local antiproliferative drug delivery. Methods: Anti-tissue factor (TF) nanoparti- 
cias incorporating 0 mol%, 0.2mo1% or 2.0 mol% paclitaxel or doxorubicin were targeted 
to VSMC in vitro for 30 minutes and cellular proliferation was determined 3 days later. 
Results: VSMC proliferation was decreased (p<0,05) 0%, 75% and 81% by TF-targeted 
paslitaxel nanoparticles (Fig) and by 0%, 59% and 72% for TF-targeted doxorubicin 
nanoparticias, respectively. Effective drug delivery depended on the interaction of the 
drug-iaclen anoparticia surface with the target cell membrane, which was facilitated by 
the ligand-surfaca ttachments. 
• NON -TARGETED TAXOL NANOPARTICLF.8 
I"1 TARGETED TAXOL NANOPARTICL_E8 
Conclusion: TF-targeted paramagnetic nanoparticles can be employed to directly deliver 
antiproliferative therapy to VSMC in a new clinical paradigm that could circumvent he 
deleterious ide-effects often associated with drug-eluting stent-besed approaches. 
4:45 p.m. 
872-4 Decorln Overexpresslon In the Arterial Well Prevents 
Neolntime Formetlon and Collagen Accumulet lon 
Following Balloon Angloplasty 
Asim N, Cheema. Nafiseh Nili, Alan W, Barolet, Jacek Unda, Balplng Qiang, Mohammed 
R. Eskandadan, Frank J. Giordano, John Sparkes, Bradley H. Strauss, St. Michael's 
Hospital, Toronto, Ontario, Canada. 
Extracalluiar matrix (ECM) plays a cdtical role in the development of restenosis after bal- 
loon angiopiasty (BA). Collagen is the major ECM protein and its accumulation is an 
important mechanism of restenosis. In-vitro studies from our laboratory have shown that 
dacodn, a small proteoglycan, inhibits collagen synthesis in cultured smooth muscle 
cells. Therefore, we evaluated the in-vivo effects of decorin overexpression in the vessel 
wall. 
BA was performed in a double injury model of restenosis in rabbit carotid arteries. Aden- 
oviral-DNA constructs encoding for either betagaiactosidese (B-gal) or decorin were 
administered intraluminally at the time of 2nd injury. A third group (control) only recaivod 
2 balloon injuries without gene transfection. Animals were sacrificed at 10 weeks after 
2nd injury. The treated arteries (n=12 per group) were removed and analyzed for col- 
lagen content and by morphometry. 
The intimal area (mean:t:SD, mm 2) of dacofin group was 0.29-/-0.12 compared to 
0.42t-0.14 in the t3-gal and 0.48±O.16 in the control group (p<0.05, compared to control 
and =3-gal). Total collagen content (mean:l:SD, pg/OH proline per artedal segment) in the 
decofin group was 228198 compared to 343d:109 in the B-gel and 411+331 in the control 
group (p<0.04, compared to control and 6,gel). 
Adenoviral mediated decodn overexpression inhibits neointima formation and collagen 
accumulation after balloon injury. These findings suggest a possible therapeutic role for 
decorin in the treatment of restenosis after BA. 
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880-1 Three-Dimensional IVUS Amnment  of Edge Effects 
Following Drug-Elutlng Stent Implantetlon 
Toru Kataoka. Eberhard Grubs, Yasuhiro Honda, Karl E. Hauptmann, Yoshihiro Modno, 
Seung-Ho Hut, Paul G. Yock, Peter J. Fitzgerald, SCORE investigators group, Stanford 
University. Stanford, Cafifornia, Heart Center Siogburg, Siegburg, Germany. 
Drug-eluting stents produce a stdking reduction of nsointimal growth within the stant. 
However, potential edge effects have not been systematically investigated. The purpose 
of this study was to use sedal 3-D IVUS to evaluate the long-term vessel response at 
adjacent reference segments of the QUANAM QP2 (a taxol analogue)-eluting stent 
(DES) compared to bare metal stants (BMS). 
Methods: Sedal (baseline and 6-month follow-up) IVUS images of 69 stont edges in 40 
patients (20 DES; 20 BMS) were analyzed in SCORE, a randomized trial comparing DES 
vs. BMS. External elastic membrane (EEMA), plaque (PA), and lumen areas (LA) were 
measured at every 1 mm cross-section within 5 mm outside of both stant margins. Area 
changes (4) were computed as follow-up minus baseline. 
Results: Baseline lesion and procedural characteristics were similar in'the two groups. 
Overall, DES had a slightly greater mean APA at the stent edges than BMS (DES 
0.63±1.35 vs BMS 0.03d:1.01 mm 2, p=0.04). However, mean ~.LA was similar in the two 
groups (DES -0.31±1.25 mm 2 vs BMS -0.63+1.31 mm 2, ns) due to an increase in mean 
EEMA in DES (,~EEMA: DES 0.35~1.51 vs BMS -0.60±1.51 mm 2, p=0.01). Figure shows 
~,EEMA, ApA, and ,~LA over the stent edges. 
Conclusions: This 3-D IVUS analysis of SCORE revealed no evidence of negative edge 
effects following the QP2-eluting stent implantation as compared to bare metal stents. 
The preservation of edge lumen with the QP2-eluting stant was due to a prevention of 
vessel shrinkage, particularly at the distal reference. 
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880-2 Edge Effect Does Not Occur After Implantation of 
Sirollmus-Eluting Stents: A Three-Dimensional 
Intravascular Ultrasound Analysis From the RAVEL Trial 
Andrea S. Abizald. J. Eduardo Souse,, Pim de Feyter, Aiaxandra Abizald, Egon Wualfert, 
William Wijns, Marie C. Morice, Giulio Guagliumi, Antonio Colombo, Patrick Serroys, 
Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil, Lenox Hill Heart and 
Vascular Institute, Cardiovascular Research Foundation, New York, New York. 
Background: Edge lumen loss, the so-called "edge effect,' is one of the limitations of 
brechytherapy, especially after implanting beta-emitting stects. The purpose of the cur- 
rent analysis is to determine whether edge effects also occur after implantation of simli- 
mus-aluting stents. Methods: The RAVEL trial, a placebo-controlled randomized 
multicanter study, compared sirolimus-eluting (SE) Bx Velocity TM stants (Cypher TM) ver- 
sus uncoated Bx Velocity TM stents in 237 pts with single, de novo lesions in native coro- 
nary arteries. All patients received clopidogrel for a 2-month period. Serial volumetric 
intravascular ultrasound (IVUS) analysis was performed in 95 patients at 6 months fol- 
low-up. The volumetric analysis included 5mm long reference segments adjacent to the 
proximal and distal edges of the stent. Mean cross-sectional area results over the length 
of the reference segments are reported. Results: In pts treated with SE stents, there was 
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no episode of rastenosis either within the stent or at the stant edges. IVUS results (Table) 
show no difference when SE stent edges were compared to placebo stent edges. To the 
contrary, there was a tendency for reference lumen areas to be larger and plaque areas 
to be smaller in SE stants, especially at the distal edge. 
SE etent Bare etlmt A p-value 
N=48 N=47 
Proximal edge 
Artedal area, mm 2 14.76+5.05 13.89-1"3.69 0.87 0.37 
Lumen area, mm 2 7.65-J:3.37 6.84+~.61 0.81 0.22 
Plaque area, mm 2 7.11:~2..90 7.05:P.2.52 -0.06 0.91 
Distal edge 
Arfedal area, mm 2 11.59~:4.08 11.46+3.70 0.13 0.88 
Lumen area, mm 2 6.68+~.30 5.69~1.91 0.99 0.03 
Plaque area, mm 2 4.90+_2.53 5.77:P.2.97 0.86 0.16 
Basel~e MSA (sqrnm) Bmllne MSA (Nmm) 
Conclusions: Volumetric IVUS analysis shows that there is no "edge effect' when siroli- 
mus-eluting stants are used to treat de novo, native coronary lesions. 
9:00 a.m. 
880-3 Optimal Endpoint for  Drug-Eluting Stent: Pradletlve 
Value of Min imum Stent Area for Long-Term Stent 
Patency 
Yasohiro Honda, Eberhard Grube, Toru Kataoka, Karl E. Hauptmann, Yoohihiro Modnc, 
Seung-Ho Hur, Paul G. Yock, Peter J. Fitzgerald, SCORE investigators group, Stanford 
University, Stanford, California, Heart Center Siogburg, Siegburg, Germany, 
Minimum stant area (MSA) has been shown to be a consistent predictor of instant rest- 
enosis. However, its predictive value is limited because of biologic variability in the rest- 
enosis process. Drug-eluting stents (DES) provide a biological effect as well as a 
mechanical solution to obstructive lesions. The aim of this study was to investigate the 
relationship between post-procedure MSA and long-term stent patancy following the 
QUANAM QP2-eluting stent (DES) implantation as compared to bare metal stents 
(BMS). 
Methods: SCORE is a randomized trial comparing DES vs. BMS. To date, serial IVUS 
(baseline and 6-months) studies are available in 64 (DES 30: BMS 34) of 118 enrolled 
patients. MSA at post-procedure and minimum lumen area (MLA) at follow-up were 
obtained. 
Results: The baseline charactadstics were similar in DES and BMS. In BMS, only a 
weak correlation was observed between post-procedure MSA and follow-up MLA 
(r--0.37, p--0.03), potentially reflecting high variability in biological activity of individual 
lesion/patients. DES, however, showed a significant positive relationship with a high cor- 
relation coefficient between the two parameters (r=0.73, p<0.0001). 
Conclusions: Preliminary IVUS results suggest that past-procedure MSA may predict 
long-term stent patancy more accurately in DES than in BMS. This finding indicates that 
post-procedure MSA, a simple mechanical index, can be used as the optimal procedural 
endpoint for DES, regardless of variable degrees of biological activity in each lesion. 
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880-4 Total Supprmmlon of  Neolntimal Prol i feration After 
Implantation of Slrol lmus-Elut lng Stents: Volumetric 
Intravascular Ultrasound Results From the Randomized 
RAVEL Trial 
Alexandre Abizaid, Patdck Serruys, J. Eduardo Souse, Pim de Feyter, Andrea Abizald, 
Antonio Colombo, Giuiio Guagliumi, William Wijns, Egon Wuelfert, Made C. Morice, 
Institute Dante Pazzansse of Cardiology, Sao Pau/o, Brazil. 
Background: We previously showed, in a non-rendomized study, that Sirolimus-Eluting 
(SE) stents inhibit noeintimal proliferation. These preliminary results were tested in 
RAVEL, a double-blinded, randomized, placedo-controlled multicentar trial that com- 
pared SE BX Velocity stents (n=120) vs bare BX Velocity stenta (BS, n=118). Methods: 
The intravascular ultrasound (IVUS) sub-study included 95 pts (SE=48 and BS=47). 
Results: 
6-Month IVUS FU Sirolimus-eluting Bare stant P values 
Stant volume (mm3) 130.6-3:33.9 132:1:1 +35.6 0.842 
Lumen volume (ram3) 128.9~33.9 94.9.~40.9 < 0.0001 
Intimal hyperplasia volume (ram 3) 1.97+4.87 37.2¢27.8 < 0.0001 
Intimal hyperplesla (% of stant volume) 1.45:1:2.83 28.8+19.7 < 0.0001 
The cumulative frequency distribution curve of percent obstruction shows that 90% of the 
SE group had less than 2% of the stent occupied by neointima (left curve, Figure). Con- 
cluslons: In the RAVEL trial, IVUS analysis shows a striking inhibition of intimal hyper- 
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880-5 In t ravncu lar  Ultrasound Assessment Five Years After 
Intracoronary Gamma Radiation Therapy 
Joroe Luna-Guerra, Jos(~ A. Condado, Jorge F. Saucado, Orlando Gurdial, Isabel ifurria, 
Bogart Parra, Ron Waksman, Peter J. Fitzgerald, Paul G. Yock, Stanford University 
School of Medicine, Stanford, California, Hospital "Miguel Pdrez Carrsr~o', Caracas, 
Venezuela. 
BACKGROUND: Late effects of intracoronary gamma radiation remain unknown, as 
moot long-term studies of efficacy and potential side effects have been initiated within the 
past 3 years. We report five-year intravascular ultrasound (IVUS) findings from the initial 
cohort of patients treated with intrecoronary brechytherepy in Venezuela. 
METHOD: IVUS examinations were performed in 14 patients (15 lesions) 5 years after 
they were treated with non-centered 1921r in doses of 19-55 Gy after PTCA. IVUS inter- 
rogations were performed by manual pullback using a dynamic aperture catheter system 
(in-Vision, EndoSonioo Corp., Rancho Cordova, CA) and were analyzed off-line using 
quantitative methods (QCU) by a commercially available software package (Quent32, 
Sanders Data Systems, Palo Alto, CA). 
RESULTS: At5 years, the mean minimum lumen area (MLA) atthe treated segment was 
3.6¢1.9 ram2 (range, 0 to 8 ram), and the mean % area stenosis (%AS) at the irradiated 
segment was 50.5:P.22.9 (range, 19.4 to 100 %). IVUS defined (%AS >70%) restenosis 
was present in 4 arteries (26.7%), two of which occurred at edges. Positive remodeling 
was obsewed in 9 artedes (60%), and three true coronary aneurysms were observed (2 
focal, 1 fusiform) without evidence of thrombus, increased echo intensity of adventitia, 
presumably due to fibrosis, of moderate or greater degree occurred in 11 artades 
(73.3%). Calcification was observed in 9 arfedes (60%), mostly as >90 degree arcs and 
of deep or mixed location. 
CONCLUSIONS: In this five-year IVUS cohort, gamma radiation was associated with 
modest plaque/neointima ccumulation. Positive remodeling was common and there 
were three aneurysms (previously detected by anglo). The most striking new finding was 
fibrosis of the adventitia nd extensive deep and mixed calcification in the majodty of the 
treated segments. 
9:45 a.m. 
880-6 Perl-Stent Remodel ing and Neolntlmal Response 
Fol lowing Intracoronary Radiation Therapy: A 
Volumetric Intravascular Ultrasound Study 
Hirovuki Okure. Yasuhiro Honda, David P. Lee, Shinjou Sonoda, Mamoo Nakamura, 
Grzegorz L. Kaluza, Nadir M. All, Paul G. Yock, Albert E. Raizner, Peter J. Fitzgerald, 
Stanford University, Stanford, California, Baylor College of Medicine, Houston, Texas. 
A recent volumetric IVUS study has suggested the role of peri-stent remodeling in subse- 
quent neointimal response. The aim of this study was to investigate the potential relation- 
ship between peri-stent remodeling and neointimal proliferation following intracoronary 
brechytherepy with a beta source wire (32p). 
Methods: Sedal (baseline and follow-up) volumetric IVUS analyses were performed in 
23 stentad lesions treated with intrecoronary beta radiation enrolled in the PREVENT 
study. Vessel (W), stent (SV) and lumen volumes (LV) were obtained using Simpaon's 
method. The volumes of plaque and neointima outside the stent (ped-stant volume, PSV) 
and neointima within the stent (intrastent volume, ISV) were computed. Peri-stant remod- 
eling was defined present if AVV > 0 (Group P) and absent if AVV_<0 (Group N). 
Results: At baseline, W, LV, SV, PSV and ISV were similar between Group P (n=12) 
